Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study

NCT07733050 is registered in ClinicalTrials.gov with Shanghai General Hospital, China as lead sponsor.

NCT NCT07733050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07733050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study
Lead sponsor
Shanghai General Hospital, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 1, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma